Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7


Acidosis Drives the Reprogramming of Fatty Acid Metabolism in Cancer Cells through Changes in Mitochondrial and Histone Acetylation.

Corbet C, Pinto A, Martherus R, Santiago de Jesus JP, Polet F, Feron O.

Cell Metab. 2016 Aug 9;24(2):311-23. doi: 10.1016/j.cmet.2016.07.003.


Inhibition of glucose metabolism prevents glycosylation of the glutamine transporter ASCT2 and promotes compensatory LAT1 upregulation in leukemia cells.

Polet F, Martherus R, Corbet C, Pinto A, Feron O.

Oncotarget. 2016 Jul 19;7(29):46371-46383. doi: 10.18632/oncotarget.10131.


Empowerment for the Right to Health: The Use of the "Most Significant Change" Methodology in Monitoring.

Polet F, Malaise G, Mahieu A, Utrera E, Montes J, Tablang R, Aytin A, Kambale E, Luzala S, Al-Ghoul D, Darkhawaja RA, Rodriguez RM, Posada M, De Ceukelaire W, De Vos P.

Health Hum Rights. 2015 Dec 10;17(2):71-82.


A new ER-specific photosensitizer unravels (1)O2-driven protein oxidation and inhibition of deubiquitinases as a generic mechanism for cancer PDT.

Pinto A, Mace Y, Drouet F, Bony E, Boidot R, Draoui N, Lobysheva I, Corbet C, Polet F, Martherus R, Deraedt Q, Rodríguez J, Lamy C, Schicke O, Delvaux D, Louis C, Kiss R, Kriegsheim AV, Dessy C, Elias B, Quetin-Leclercq J, Riant O, Feron O.

Oncogene. 2016 Jul 28;35(30):3976-85. doi: 10.1038/onc.2015.474. Epub 2015 Dec 21.


Reducing the serine availability complements the inhibition of the glutamine metabolism to block leukemia cell growth.

Polet F, Corbet C, Pinto A, Rubio LI, Martherus R, Bol V, Drozak X, Grégoire V, Riant O, Feron O.

Oncotarget. 2016 Jan 12;7(2):1765-76. doi: 10.18632/oncotarget.6426.


The SIRT1/HIF2α axis drives reductive glutamine metabolism under chronic acidosis and alters tumor response to therapy.

Corbet C, Draoui N, Polet F, Pinto A, Drozak X, Riant O, Feron O.

Cancer Res. 2014 Oct 1;74(19):5507-19. doi: 10.1158/0008-5472.CAN-14-0705. Epub 2014 Aug 1.


Supplemental Content

Support Center